Guess which ASX 200 company co-founders just sold $118 million in shares

This ASX 200 healthcare share is trading lower following the mammoth off-market block trade.

| More on:
A man and a woman sit in front of a laptop looking fascinated and captivated.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) fell 9.4% to an intraday low of $27.52 as the market digested news of a $118 million off-market trade by the co-founders.

The radiopharmaceutical company's CEO, Dr. Christian Behrenbruch, and former director, Dr. Andreas Kluge, both sold two million shares each in an off-market block trade this week.

The shares were sold for $29.50 apiece after the market close on Wednesday.

Let's find out more.

ASX 200 healthcare share dips following block trade

Telix Pharmaceuticals shares closed at $31.05 on Wednesday.

Hence, the block trade was executed at a 5% discount.

The Australian Financial Review (AFR) reported that JPMorgan had been appointed to shop the four million shares around after the day's trading session finished on Wednesday.

Dr Behrenbruch sold his shares as part of his divorce settlement and for estate planning purposes. The shares sold were held in a family trust.

Dr Behrenbruch has committed not to sell any more Telix shares for the next 12 months.

The company said the sale represented less than 10% of Dr Behrenbruch's holdings. Following the trade, he now holds 6.3% of Telix's issued capital.

The Telix board approved the sale to occur within a permitted trading window following the release of the company's full-year FY24 results on 20 February.

In a statement, Telix said:

As Managing Director and Group CEO and a major shareholder, Dr. Behrenbruch is committed to Telix's future and has no intention to sell further shares in the foreseeable future.

Telix announced Dr Behrenbruch's pending sale after the market close on Wednesday.

The company confirmed the transaction in a second announcement before the market open yesterday.

In that statement, Telix also revealed that Dr. Andreas Kluge had also sold 2 million shares as part of the block trade.

Management said Dr Kluge's remaining Telix shares would also be subject to a twelve-month lock-up arrangement.

Telix said Dr Kluge has confirmed that he has no intention to sell further shares in the foreseeable future.

Telix announced Dr Kluge's retirement from the board on 17 October last year.

The company said Dr Kluge would be engaged by Telix on a consultancy basis to provide strategic advice and clinical input.

What else is news with Telix Pharmaceutical shares?

Last week, Telix reported a remarkable 860% lift in net profit after tax (NPAT) to $49.9 million for the full year FY24.

The company also revealed a 56% increase in revenue to $783.2 million.

Management is guiding FY25 revenue of between $1.18 billion and $1.23 billion.

This would represent an annual increase of approximately 51% to 57%, respectively.

ASX 200 healthcare share price snapshot

The ASX 200 healthcare share has risen 139% over the past 12 months.

The Telix Pharmaceutical share price hit an all-time high of $31.97 on Wednesday.

Created with Highcharts 11.4.3Telix Pharmaceuticals PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Healthcare Shares

These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Up 250% in a year, how much higher can this ASX healthcare share climb?  

The future looks promising for this biotech firm after delivering a record-quarterly result.

Read more »

shadow of a man looking out a window with arrows signifying falling share price
Healthcare Shares

Macquarie expects this ASX All Ords healthcare stock to fall 21% in FY26

The company faces several headwinds across multiple divisions.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Top broker names the best ASX healthcare shares to buy in FY26

Bell Potter has good things to say about these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is jumping on record quarter?

This stock reported record sales during the past three months.

Read more »